Holen Sie sich die Stockscreener-App
29.77
3.44%
0.99
Sutro Biopharma Inc Aktie (STRO) Neueste Nachrichten
Sutro Biopharma Hits New 52-Week High - National Today
Sutro Biopharma (NASDAQ:STRO) Reaches New 52-Week HighHere's What Happened - MarketBeat
Momentum Shift: Is Sutro Biopharma Inc benefiting from interest rate changes2026 Drop Watch & Low Risk High Reward Trade Ideas - baoquankhu1.vn
Sutro Biopharma (STRO) price target decreased by 21.62% to 29.58 - MSN
Sutro Biopharma Receives 'Moderate Buy' Rating from Analysts - National Today
Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Sutro Biopharma, Inc. (STRO) stock price, news, quote and history - Yahoo Finance UK
Sutro Biopharma (STRO) Moves 7.4% Higher: Will This Strength Last? - Yahoo Finance
Leerink Partners Initiates Sutro Biopharma at Outperform With $38 Price Target - Moomoo
Rate Cut: What is the Moat Score of Sutro Biopharma IncWeekly Trading Summary & Safe Capital Growth Plans - baoquankhu1.vn
Leerink Partners initiates Sutro Biopharma stock with outperform rating - Investing.com
Leerink Partners initiates Sutro Biopharma stock with outperform rating By Investing.com - Investing.com India
Leerink Partners initiates coverage of Sutro Biopharma (STRO) with outperform recommendation - MSN
Institution Moves: What is the Moat Score of Sutro Biopharma IncWeekly Risk Report & Risk Adjusted Swing Trade Ideas - baoquankhu1.vn
Sutro Biopharma Hits New 52-Week High at $26.54, Up 548.83% - Markets Mojo
[EFFECT] SUTRO BIOPHARMA, INC. SEC Filing - Stock Titan
Market Outlook: Can Sutro Biopharma Inc continue delivering strong returns2026 Valuation Update & Long-Term Safe Investment Ideas - baoquankhu1.vn
Sutro Biopharma enters sales agreement, may offer & sell shares of common stock of up to $100 millionSEC filing - marketscreener.com
Sutro Biopharma Enters Sales Agreement, May Offer & Sell Shares Of Common Stock Of Up To $100 MillionSEC Filing - TradingView
Sutro Biopharma (NASDAQ: STRO) files $100M ATM shelf with TD Cowen - Stock Titan
Gains Report: Why is Sutro Biopharma Inc stock going down2026 Spike Watch & Fast Gain Swing Trade Alerts - baoquankhu1.vn
Earnings Risk: Is now the right time to enter Sutro Biopharma IncWeekly Stock Summary & Weekly Watchlist for Consistent Profits - baoquankhu1.vn
Value Recap: Is Sutro Biopharma Inc in a bullish channelMarket Sentiment Summary & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Sutro Biopharma (STRO) price target increased by 13.85% to 37.74 - MSN
Hedge Fund Bets: What is the Moat Score of Sutro Biopharma Inc2026 Earnings Surprises & Technical Analysis for Trade Confirmation - baoquankhu1.vn
Sutro Biopharma (NASDAQ:STRO) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Stock Market Recap: Is Sutro Biopharma Inc a potential multi baggerSell Signal & Reliable Intraday Trade Alerts - baoquankhu1.vn
HC Wainwright Lowers Earnings Estimates for Sutro Biopharma - marketbeat.com
Sutro Biopharma (NASDAQ:STRO) Upgraded by Truist Financial to "Strong-Buy" Rating - MarketBeat
Sutro Biopharma Faces Rising Operational Risks Amid Escalating U.S.-China Trade Tensions - The Globe and Mail
Sutro Biopharma Inc buy Deutsche Bank Aktiengesellschaft - sharewise.com
Analyst James Shin Raises Price Target for Sutro Biopharma (STRO) to $55.00 | STRO Stock News - GuruFocus
Deutsche Bank Aktiengesellschaft Issues Positive Forecast for Sutro Biopharma (NASDAQ:STRO) Stock Price - MarketBeat
Deutsche Bank Adjusts Sutro Biopharma Price Target to $55 From $51, Maintains Buy Rating - MarketScreener
HC Wainwright Predicts Sutro Biopharma FY2030 Earnings - MarketBeat
This Ralph Lauren Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday - Benzinga
Wells Fargo Upgrades Sutro Biopharma (STRO) with Significant Pri - GuruFocus
Sutro Biopharma (NASDAQ:STRO) Raised to "Overweight" at Wells Fargo & Company - MarketBeat
Sutro Biopharma (NASDAQ:STRO) Raised to Buy at HC Wainwright - MarketBeat
Wells Fargo Upgrades Sutro Biopharma to Overweight From Equal Weight, Adjusts PT to $27 From $8 - MarketScreener
H.C. Wainwright upgrades Sutro Biopharma stock rating to buy By Investing.com - Investing.com Canada
H.C. Wainwright upgrades Sutro Biopharma stock rating to buy - Investing.com
Sutro's FY25 Net Loss Narrows; On Track To Report Initial Phase 1 Data Of STRO-004 In Mid-2026 - RTTNews
Citizens reiterates Sutro Biopharma stock rating on pipeline progress By Investing.com - ca.investing.com
STRO Stock: HC Wainwright & Co. Upgrades Sutro Biopharma | STRO - GuruFocus
Sutro Biopharma (STRO) Receives Upgrade with Promising Outlook - GuruFocus
Citizens reiterates Sutro Biopharma stock rating on pipeline progress - Investing.com
Sutro Biopharma Reports 2025 Financial Results, Advances Dual-Payload ADC Pipeline, and Extends Cash Runway to 2028 - Minichart
Sutro Biopharma Annual Report 2023: Business Overview, Risk Factors, and Financial Analysis - Minichart
Sutro Biopharma Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Sutro Biopharma (NASDAQ: STRO) launches $100M ATM program with TD Cowen - Stock Titan
Sutro Biopharma Ends ATM Agreement After 2025 Results - TipRanks
Sutro Biopharma Reports Full Year 2025 Financial Results and Business Highlights - Bitget
Sutro Biopharma (NASDAQ:STRO) Issues Earnings Results - marketbeat.com
Sutro Biopharma 2025 10-K: $102.5M revenue, $(22.49) EPS - TradingView
Sutro Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Sutro Biopharma (NASDAQ: STRO) expands ADC pipeline and monetizes partnerships - Stock Titan
Revenue jumps as Sutro Biopharma (NASDAQ: STRO) narrows 2025 loss - Stock Titan
Q4 financial results released by Sutro Biopharma with operational update - Traders Union
BRIEF-Sutro Biopharma FY Revenue USD 102.484 Million Vs. IBES Estimate USD 99.2 Million - TradingView
Sutro Biopharma (STRO) 2024 Wells Fargo Healthcare Conference Summary - Quartr
If You Invested $1,000 in Sutro Biopharma (STRO) - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
2.69%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):